Abstract:10116 Background: This phase III double-blind study was conducted to provide bridging data to the available efficacy and safety data of denosumab (DmAb) from global skeletal-related events (SRE)-prevention studies, by comparing DmAb with zoledronic acid (ZA). Methods: Patients aged ≥18 years who had a confirmed solid tumor, evidence of ≥1 bone metastasis and ECOG score 0-2 were enrolled. Patients were randomized (2:1) to receive either DmAb 120 mg subcutaneously every 4 weeks (Q4W) or ZA 4 mg intravenously Q4W for 49 weeks (wks) and are being followed up to Wk 73. The primary endpoint was percent change in urinary amino-terminal cross-linking telopeptide of type I collagen, corrected for urine creatinine (uNTx/uCr) from baseline (BL) to 13 wks. Other endpoints were percent change in bone-specific alkaline phosphatase (S-BALP) from BL to 13 wks and time to first on-study SRE. Safety and tolerability were assessed including collecting all adverse events (AEs) and performing vital signs measurement and a standard panel of laboratory tests. Results: A total of 485 (DmAb=326, ZA=159) pts were randomized; 90% of pts had either completed the study or withdrawn by planned data cut-off (29 February 2016). Mean (SD) age of pts was 53.9 (11.38) years; 67% pts were women, 93% Chinese, 50% had breast cancer and 27% had non-small cell lung cancer. The mean change in uNTx/uCr from BL to Wk 13 was -81.9% for DmAb and -75.2% for ZA (ANCOVA; p<0.0001). The median change in S-BALP from BL to Wk 13 was -36.8% (DmAb) and -30.3% (ZA) (p=0.027). Rate of developing any on-study SRE within the first year after initializing treatment was lower in pts receiving DmAb vs ZA (4.9% vs 6.3%) without statistical significance. Incidence of AEs was similar in DmAb and ZA groups (89% vs 91%), with most common AEs being anemia (25% vs 24%), white blood cell count decreased (21% vs 24%), and pyrexia (13% vs 21%); overall incidence of serious AEs: 14% vs 9%. One serious AE (muscular weakness) was reported as related to study treatment. Conclusions: DmAb was found to be superior than ZA in reducinguNTx/uCr in overall and Chinese pts. No new safety concerns were identified with DmAb. Clinical trial information: NCT01920568.

Denosumab improves bone mineral density and microarchitecture in rheumatoid arthritis: randomized controlled trial by HR-pQCT

The Efficacy of Denosumab in Patients With Rheumatoid Arthritis: A Systematic Review and Pooled Analysis of Randomized or Matched Data

Association of denosumab with serum cytokines, chemokines, and bone-related factors in patients with rheumatoid arthritis: A post hoc analysis of a multicentre, open-label, randomised, parallel-group study

Efficacy and Safety of Denosumab in Postmenopausal Women with Osteoporosis

THU0184 Repair of Bone Erosion in Rheumatoid Arthritis by Denosumab: an HR-pQCT Study:

Effect of Denosumab Switched from Bisphosphonates in Preventing Joint Destruction in Postmenopausal Rheumatoid Arthritis Patients with Anti-Cyclic Citrullinated Peptide Antibodies

Comparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritis

Preferable effect of CTLA4-Ig on both bone erosion and bone microarchitecture in rheumatoid arthritis revealed by HR-pQCT

Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot study

Effect of denosumab , a fully human monoclonal antibody to RANKL , on bone mineral density and fractures : a meta-analysis

Comparison of Clinical Efficacy and Safety Between Denosumab and Alendronate in Postmenopausal Women with Osteoporosis: a Meta-Analysis

Denosumab effect on bone mineral density and urinary-NTX in breast cancer patients receiving aromatase inhibitors

The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results

Denosumab Versus Risedronate in Glucocorticoid‐Induced Osteoporosis: Final Results of a Twenty‐Four–Month Randomized, Double‐Blind, Double‐Dummy Trial

Denosumab ameliorates osteoarthritis by protecting cartilage against degradation and modulating subchondral bone remodeling

Effect of denosumab, an anti-osteoporosis drug, on vascular calcification: A meta-analysis

Impact of Bone Mineral Density and Bone Structural Properties on Postmenopausal Women With Rheumatoid Arthritis in Japan: A Cross-Sectional Study

A Double-Blind, Double-Dummy, Randomized Controlled, Multicenter Trial Of Tc-99-Methylene Diphosphonate In Patients With Moderate To Severe Rheumatoid Arthritis

Efficacy and Safety of Denosumab from A Phase Iii, Randomized, Active-Controlled Study Compared with Zoledronic Acid in Patients of Asian Ancestry with Bone Metastases from Solid Tumors.

The clinical assessment of changes in bone density in Rheumatoid Arthritis patients': Role of DEXA scan and bone turnover biomarkers

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors